<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4242753</article-id><article-id pub-id-type="publisher-id">1470-7330-14-S1-O29</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-O29</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Role of molecular imaging in the detection of neuroendocrine tumour</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Wild</surname><given-names>Damian</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Division of Nuclear Medicine, University Basel Hospital, Basel, 4052, Switzerland</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>O29</fpage><lpage>O29</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Wild; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Wild; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/O29"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec><title/><p>Neuroendocrine tumours (NETs) have distinct biological and clinical characteristics, in particular a high density of somatostatin receptors at the cell membrane [<xref ref-type="bibr" rid="B1">1</xref>]. It is this property that allows the use of radiolabelled somatostatin analogues for imaging of these tumours. Importantly, somatostatin receptor PET/CT imaging (e.g. <sup>68</sup>Ga-DOTATOC, <sup>68</sup>Ga-DOTATATE, <sup>68</sup>Ga-DOTANOC) is superior to somatostatin receptor scintigraphy including SPECT/CT [<xref ref-type="bibr" rid="B2">2</xref>] and <sup>18</sup>F-DOPA PET/CT [<xref ref-type="bibr" rid="B3">3</xref>] in the detection of gastroenteropancreatic neuroendocrine tumours (GEP NETs).</p><p>NETs, however, have a wide range of cellular differentiation. <sup>18</sup>F-FDG PET/CT is of limited value in well-differentiated NETs but of high value in poorly differentiated NETs. Somatostatin receptor PET/CT shows contrary results [<xref ref-type="bibr" rid="B4">4</xref>]. As both <sup>18</sup>F-FDG PET/CT and somatostatin receptor PET/CT exploit distinct tumour characteristics they are complementary for tumour staging.</p><p>Small insulinomas are difficult to detect with <sup>18</sup>F-FDG PET/CT, somatostatin receptor PET/CT, <sup>18</sup>F-DOPA PET/CT and morphological imaging. Targeting of Glucagon-like peptide-1 receptors using radiolabelled exendin-4 has shown to be highly effective in the detection of these tumours [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Clinical studies have shown higher tumour uptake of radiolabelled somatostatin receptor antagonists than somatostatin receptor agonists [<xref ref-type="bibr" rid="B6">6</xref>]. As a result radiolabelled somatostatin receptor antagonists may have a significant impact on imaging of NETs.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Reubi</surname><given-names>JC</given-names></name><name><surname>Waser</surname><given-names>B</given-names></name><article-title>Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2003</year><volume>30</volume><fpage>781</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1007/s00259-003-1184-3</pub-id><pub-id pub-id-type="pmid">12707737</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Treglia</surname><given-names>G</given-names></name><name><surname>Castaldi</surname><given-names>P</given-names></name><name><surname>Rindi</surname><given-names>G</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name><name><surname>Rufini</surname><given-names>V</given-names></name><article-title>Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis</article-title><source>Endocrine</source><year>2012</year><volume>42</volume><fpage>80</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1007/s12020-012-9631-1</pub-id><pub-id pub-id-type="pmid">22350660</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Ambrosini</surname><given-names>V</given-names></name><name><surname>Tomassetti</surname><given-names>P</given-names></name><name><surname>Castellucci</surname><given-names>P</given-names></name><name><surname>Campana</surname><given-names>D</given-names></name><name><surname>Montini</surname><given-names>G</given-names></name><name><surname>Rubello</surname><given-names>D</given-names></name><etal/><article-title>Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2008</year><volume>35</volume><fpage>1431</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1007/s00259-008-0769-2</pub-id><pub-id pub-id-type="pmid">18418596</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Kayani</surname><given-names>I</given-names></name><name><surname>Bomanji</surname><given-names>JB</given-names></name><name><surname>Groves</surname><given-names>A</given-names></name><name><surname>Conway</surname><given-names>G</given-names></name><name><surname>Gacinovic</surname><given-names>S</given-names></name><name><surname>Win</surname><given-names>T</given-names></name><etal/><article-title>Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG</article-title><source>Cancer</source><year>2008</year><volume>112</volume><fpage>2447</fpage><lpage>2455</lpage><pub-id pub-id-type="doi">10.1002/cncr.23469</pub-id><pub-id pub-id-type="pmid">18383518</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Christ</surname><given-names>E</given-names></name><name><surname>Wild</surname><given-names>D</given-names></name><name><surname>Ederer</surname><given-names>S</given-names></name><name><surname>Behe</surname><given-names>M</given-names></name><name><surname>Nicolas</surname><given-names>G</given-names></name><name><surname>Caplin</surname><given-names>ME</given-names></name><etal/><article-title>Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study</article-title><source>Lancet Diabetes Endocrinol</source><year>2013</year><volume>1</volume><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(13)70049-4</pub-id><pub-id pub-id-type="pmid">24622317</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Wild</surname><given-names>D</given-names></name><name><surname>Fani</surname><given-names>M</given-names></name><name><surname>Behe</surname><given-names>M</given-names></name><name><surname>Brink</surname><given-names>I</given-names></name><name><surname>Rivier</surname><given-names>JE</given-names></name><name><surname>Reubi</surname><given-names>JC</given-names></name><etal/><article-title>First clinical evidence that imaging with somatostatin receptor antagonists is feasible</article-title><source>J Nucl Med</source><year>2011</year><volume>52</volume><issue>1412</issue><fpage>1417</fpage><pub-id pub-id-type="doi">10.2967/jnumed.111.088922</pub-id><pub-id pub-id-type="pmid">21852357</pub-id></mixed-citation></ref></ref-list></back></article>